Teva's new royalty deal; Selecta merges with Cartesian; Vir's hepatitis data
Teva inks deal with Royalty Pharma for schizophrenia drug: The Israeli drugmaker said Monday that it will receive $100 million to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
